Zymeworks (ZYME) Other Non-Current Liabilities (2021 - 2026)
Zymeworks' (ZYME) quarterly Other Non-Current Liabilities came in at $278000.0 in Q1 2026, down 67.52% year-on-year from $856000.0 in Q1 2025, and little changed quarter-over-quarter from $278000.0 in Q4 2025.
Zymeworks (ZYME) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $278000.0 for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $278000.0, down 67.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $278000.0 (down 67.52% YoY), and the FY2025 annual result was $278000.0, down 69.88% from the prior year.
- Other Non-Current Liabilities came in at $278000.0 for Q1 2026 at Zymeworks, roughly flat from $278000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.9 million in Q3 2022 to a low of $278000.0 in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $929000.0 (2024), against an average of $1.1 million.
- Across the five-year window, Other Non-Current Liabilities sank 90.01% in 2023 and surged 217.06% in 2024, its largest moves.
- Zymeworks' Other Non-Current Liabilities stood at $1.6 million in 2022, then grew by 3.59% to $1.7 million in 2023, then plunged by 45.74% to $923000.0 in 2024, then sank by 69.88% to $278000.0 in 2025, then changed by 0.0% to $278000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $278000.0 (Q1 2026), $278000.0 (Q4 2025), and $278000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 828,000.00 |
| Mar 31, 2025 | 856,000.00 |
| Dec 31, 2024 | 923,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 293,000.00 |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 2.93 Mn |
| Dec 31, 2021 | 2.75 Mn |